Novo Nordisk is partnering with Anthropic to use Anthropic’s Claude “Science” capability and related frontier models to speed up drug discovery. Multiple outlets report the collaboration is intended to accelerate aspects of research and development, including tasks that can be supported by AI.
The sources describe the agreement as part of a wider trend among pharmaceutical companies integrating AI tools into R&D workflows. Quartz and Euronews emphasize that Novo plans to apply Claude Science to drug discovery challenges, and that the effort supports broader efforts to bring AI deeper into how new medicines are developed. The Next Web adds that Novo will test Claude Science as part of its research efforts and includes a quoted statement from Novo’s CEO about strengthening R&D and supporting Novo’s mission for health solutions for people with chronic diseases.
While outlets focus on similar core details—the partnership and the use of Claude—their wording varies between describing the deal’s purpose (speeding discovery) and situating it within the industry’s overall AI adoption.
